Zydus Cadila, an innovative global pharmaceutical company, has received an approval for Phase I clinical trial from the USFDA for ZYDPLA1 - a next generation, long-acting DPP-4 Inhibitor. ZYDPLA1 is an orally active, small molecule NCE, discovered and developed by the Zydus Research Centre, the NCE research wing of Zydus.
ZYDPLA1 is a novel compound in the Gliptin class of anti-diabetic agents. It works by blocking the enzyme Dipeptidyl Peptidase-4 (DPP-4), which inactivate the Incretin hormone GLP-1.
Currently, all available DPP-4 inhibitors are dosed once-daily, ZYDPLA1 with a once-a-week dosing regimen, would provide diabetic patients with a more convenient treatment alternative, ZYDPLA1 will offer sustained action, which will result, in an improved efficacy profile.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1680.10 |
| Dr. Reddys Lab | 1222.90 |
| Cipla | 1239.65 |
| Zydus Lifesciences | 945.05 |
| Lupin | 2320.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: